Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis

Kensuke Sakurai\(^1\), Takehiko Katsurada\(^1\), Mutsumi Nishida\(^2,3\), Satomi Omotehara\(^2,3\), Shinya Fukushima\(^1\), Shinsuke Otagiri\(^1\), Kazunori Nagashima\(^1\), Reizo Onishi\(^1\), Ryo Takagi\(^4\), Yoshito Komatsu\(^1,5\), Naoya Sakamoto\(^1\)

\(^1\)Department of Gastroenterology and Hepatology, \(^2\)Division of Laboratory and Transfusion Medicine, \(^3\)Diagnostic Center for Sonography, and \(^4\)Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo; \(^5\)Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan

Background/Aims: The usefulness of ultrasonography (US) in diseases of the gastrointestinal tract has been reported recently. This prospective study aimed to determine the features of US findings in immune-mediated colitis (IMC), an adverse event induced by immune checkpoint inhibitor, and examine the correlation between US findings, colonoscopy (CS) findings, and severity of colitis.

Methods: We studied patients examined using CS and US upon suspicion of IMC in Hokkaido University Hospital between April 2018 and February 2021. Endoscopic findings of IMC were assessed using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). The severity of US findings in IMC was evaluated using US grade, which is the ultrasonographic grading scale in ulcerative colitis. Bowel wall thickness and the intensity of the color Doppler signal were also analyzed. Severity of colitis was evaluated using Common Terminology Criteria for Adverse Events (CTCAE) grade version 5.

Results: Fourteen patients with IMC were enrolled. The US findings were bowel wall thickening, loss of stratification, ulceration and increased blood flow signal. The US grade was moderately correlated with the UCEIS (\(r=0.687, P=0.009\)) and CTCAE grade (\(r=0.628, P=0.035\)). Bowel wall thickness and UCEIS (\(r=0.628, P=0.020\)), as well as color Doppler signal grade and CTCAE grade (\(r=0.724, P=0.008\)), were significantly correlated.

Conclusions: US findings in IMC were mainly similar to those of ulcerative colitis, but there were some findings that were characteristic only of IMC. Significant correlation was found between US findings, CS findings, and severity of colitis. Hence, US could be useful for the evaluation of IMC. (Intest Res 2023;21:126-136)

Key Words: Transabdominal ultrasonography; Colonoscopy; Immune-mediated colitis; Immune checkpoint inhibitor; Immune-related adverse events

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have proven to be effective against various carcinomas, and their range of indications is continuously expanding.\(^1,4\) ICIs exhibit anti-tumor effects by activating immune responses against tumor cells. However, their activity might also cause immune dysfunction, leading to side effects such as autoimmune diseases or autoinflammatory diseases; the latter are called “immune-related adverse events” (irAEs).\(^10\) Among irAE-related studies, patients diagnosed with immune-mediated colitis (IMC) based on imaging data and abdominal symptoms accounted for 5% to 16% of those treated with anti-CTLA-4 antibodies and 1% to 2% of those treated with anti-programmed death receptor 1 (PD-1)/anti-PD-ligand 1 (PD-L1) antibodies.\(^11\) IMC can occur at any time, i.e., in some cases, IMC develops a few days after initiating treatment, while in others, enteritis develops several months after completing ICI therapy.\(^12\) Therefore, proper evaluation and treatment of diarrhea and enteritis is essential after initiating ICI therapy.\(^13\) To diagnose IMC, tests such as stool culture, Clostridium toxin test, serum cytomegalovirus antigen


Correspondence to Takehiko Katsurada, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita-15, Nishi-7 Kita-ku, Sapporo 060-8638, Japan. Tel: +81-11-716-1161, Fax: +81-11-706-7999, E-mail: tkatsu@amber.plala.or.jp

© Copyright 2023. Korean Association for the Study of Intestinal Diseases. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
test are performed to rule out infectious enteritis, and patients also undergo colonoscopy (CS). CS findings in IMC are often similar to those found in inflammatory bowel disease, particularly in ulcerative colitis (UC). Sometimes, the following findings can also be observed: patch or diffuse erythema, loss of vascular pattern, granular or edematous mucosa, exudates, aphtha, and ulceration. Further, in most cases of IMC, lesions can be found in the left colon. The treatment may consist of discontinuation of medication or the use of antidiarrheal drugs or the use of steroids and anti-tumor necrosis factor α antibodies such as infliximab. Meanwhile, cases of relapse also frequently occur after induction of remission, and enteritis has been reported to relapse in approximately 30% of patients upon resuming ICI treatment. It has been suggested that the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), a method to evaluate endoscopic severity in UC, may more accurately reflect the severity of IMC than the Common Terminology Criteria for Adverse Events (CTCAE) grade. The diagnosis of IMC is established based on CS; however, because of invasiveness and pretreatment requirements, CS cannot be used for frequent monitoring. In contrast, transabdominal ultrasonography (US) is noninvasive, does not require pretreatment, and can be performed regardless of the patient’s general physical condition. In addition, the usefulness of US in diseases of the gastrointestinal tract, such as UC and Crohn’s disease (CD), has been reported recently. With an increase in the indications for ICIs, the incidence of IMC may also increase, and modalities allowing for evaluation of the disease condition through less invasive methods will be needed. Therefore, our study aimed to elucidate the features of US findings in IMC and determine the usefulness of US in IMC.

METHODS

1. Study Design and Patients (Inclusion Criteria)
A single-center, prospective, observational study was performed at the Diagnostic Center for Sonography and Department of Gastroenterology, Hokkaido University Hospital. The study was conducted on patients being treated as outpatients or inpatients between April 2018 and February 2021 and those who underwent CS and US at Hokkaido University Hospital for suspicion of IMC at Hokkaido University Hospital. If it was difficult to conduct US and CS on the same day, these were performed within 4 days of each other. Since there are no fixed diagnostic criteria for IMC, the diagnosis was established by the attending gastroenterologist based on clinical, endoscopic and/or histological characteristics.

2. Transabdominal US
US was performed using an Apio i800/500 scanner (Canon Medical Systems, Otawara, Japan) with a center frequency of 4.75 MHz and a 6-MHz convex probe as well as a 7.5 MHz linear probe by 6 sonographers and 1 gastroenterologist, who were blinded to CS findings, with more than 5 years of experience. When US and CS were performed on the same day, a bowel cleansing agent was prescribed orally for CS before US. When US and CS were performed on different dates, the patients were fasted for at least 8 hours before US. US was performed in the supine position, and patients were repositioned when necessary. All still images and movie clips were analyzed and interpreted in a consensus manner by 2 registered sonographers (M.N. and S.O.) who had 10 or more years of experience each. They were aware of the IMC diagnosis but were blinded to the patients’ clinical information, CS findings, and other sonographers’ US assessments. The large intestine was divided into 7 segments (cecum, ascending colon, right-sided transverse colon, left-sided transverse colon, descending colon, sigmoid colon, and rectum), and the measured value at the thickest part of each segment was adopted as the bowel wall thickness (BWT). Since there has been no reported method to assess blood flow signals in the intestinal wall in IMCs, blood flow signals were assessed by classifying the color Doppler signals (CDS) into 4 grades ranging from 0 to 3, a method that we previously proposed in CD (Supplementary Fig. 1). Doppler study was performed using a 7.5-MHz linear probe, with color gain adjusted until the disappearance of noise to maximize the sensitivity. The color Doppler frequency was set from 3.3 to 4.5 MHz, with a pulse repetition frequency from 4.7 to 10.1 cm/sec, which was adjusted according to the lesion depth. The wall filter was set between 3 and 4. Similarly, there had been no reported method to assess the severity of US findings in IMC. Therefore, the severity of US findings was evaluated using US grade, which we previously proposed for severity evaluation of UC using US (Supplementary Fig. 2).

3. Colonoscopy
Using a standard endoscope (PCF-Q260AI, PCF-Q260AZI, PCF-PQ260; Olympus, Tokyo, Japan), CS was performed by 5 expert endoscopists, each of whom had performed more than 2,000 colonoscopies. A polyethylene glycol preparation was used as bowel cleansing agent. Depending on the severity, flexible sigmoidoscopy was performed without using bowel cleans-
Characteristics and usefulness of transabdominal US in IMC

Kensuke Sakurai, et al.

In this study, we aimed to evaluate the characteristics and usefulness of transabdominal US in the diagnosis of immune-mediated colitis (IMC). We hypothesized that US could provide valuable information about the severity of IMC and its progression.

Materials and Methods

The study cohort consisted of 528 patients who received immune checkpoint inhibitor (ICI) therapy from April 2018 to February 2021. Among them, 30 patients presented with diarrhea, bloody stools, or abdominal pain during ICI therapy or after discontinuation of ICI. Of these 30 patients, 18 underwent colonoscopy (CS) and ultrasonography (US) for the suspicion of IMC. Those whose CS or US showed no inflammatory findings or were diagnosed with other diseases such as infectious enteritis were excluded from the study. A total of 14 patients were enrolled who were diagnosed with IMC based on CS findings.

4. Outcomes

The outcomes are as follows: (1) the features of US findings in IMC were assessed; (2) the correlation between BWT and UCEIS or CTCAE grade of colitis was evaluated; (3) the correlation between CDS grade and UCEIS or CTCAE grade of colitis was evaluated; (4) the correlation between severity according to US and CS findings was evaluated using US grade and UCEIS; (5) the correlations between US grade, disease activity, C-reactive protein (CRP) levels, and serum albumin levels were evaluated. Disease activity was evaluated using CTCAE grade of colitis, version 5.0 (Supplementary Table 2)\(^\text{46}\); or (6) the optimal cutoff values for the sensitivity, specificity, positive predictive value, and negative predictive value of BWT, CDS grade and US grade for UCEIS or CTCAE grade of colitis were evaluated.

5. Statistical Analysis

The GraphPad Prism 8 software package (GraphPad Software Inc., San Diego, CA, USA) and JMP pro 16 (SAS Institute Inc., Cary, NC, USA) were used for statistical analyses. All variables were expressed as a median (range) or number (%). All reported P-values are two-sided, and P<0.05 was considered statistically significant. P-values were calculated using the chi-square test for categorical variables. Spearman rank correlation coefficient was used to verify the correlation between US grade, UCEIS, CTCAE grade, BWT, and CDS grade. Receiver operating characteristic (ROC) curves were constructed, and the trapezoidal rule was used to calculate the area under the ROC curve (AUROC). The optimal cutoff points for predicting UCEIS and CTCAE grade of colitis were identified based on the highest Youden index. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated using cutoff values obtained from ROC curves.

6. Ethical Considerations

This study was started after obtaining approval from the Institutional Review Board of Hokkaido University Hospital (IRB No. 017-420). The research protocol was posted on Hokkaido University Hospitals’ website, and informed consent was obtained from all patients in compliance with the Declaration of Helsinki.
RESULTS

1. Patient Enrollment
Between April 2018 and February 2021, 528 patients received ICI, 30 of them presented with diarrhea, bloody stools, or abdominal pain during ICI therapy or after discontinuation of ICI. Of these 30 patients, 18 patients underwent CS and US for the suspicion of IMC. Those whose CS or US showed no inflammatory findings as well as those who were diagnosed with other diseases such as infectious enteritis based on tissue biopsy and stool culture were excluded from the study. A total of 14 patients were enrolled who were diagnosed with IMC based on CS findings (Fig. 1).

2. Patient Characteristics
The enrolled IMC patients had a median age of 64 years (range, 47–83 years) and included 9 males and 5 females. The median body mass index was 21.6 kg/m² (range, 16.0–25.3 kg/m²). Nine and five patients suffered from IMC induced by anti-PD-1 antibodies (nivolumab in 6 cases, and pembrolizumab in 3 cases), and anti-PD-L1 antibodies (durvalumab in 1 case, atezolizumab in 4 cases), respectively. The median CTCAE grade of colitis was 3 (range, 1–3), the median duration of the period from the initial administration of ICI to the onset of IMC was 124 days (range, 12–459 days). At the onset of IMC, the median serum CRP level was 4.67 mg/dL (range, 0.05–14.90 mg/dL), and the median serum albumin level was 3.3 g/dL (range, 2.5–4.3 g/dL) (Table 1).

3. Clinical Outcomes
Among the enrolled patients, 11 (78.6%) underwent US and CS on the same day. In patients whom US and CS were performed on the same day, US was performed before CS. Complete CS was performed in 10 individuals (71.4%). Flexible sigmoidoscopy was performed in 4 individuals (28.6%) due to the severity of inflammation or insufficient colon cleansing. On the other hand, the entire large intestine was observed in 11 individuals (78.6%) using US, and values from some of the segments of the large intestine were missing in 3 individuals. Table 2 shows the visualization rate for each segment. The visualization rate for each segment tended to be higher with US than with CS, especially in the right colon. The total visualization rate in all segments were significantly higher in US observations than in those using CS ($P = 0.027$) (Table 2).

The findings found from US and those from CS are shown in Table 3, as well as their respective proportions. With US,

### Table 1. Demographic and Clinical Characteristics of Patients with Immune-Mediated Colitis

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>64 (47–83)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>Female</td>
<td>5 (35.7)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>21.6 (16.0–25.3)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Former</td>
<td>8 (57.1)</td>
</tr>
<tr>
<td>Never</td>
<td>5 (35.7)</td>
</tr>
<tr>
<td>Immune checkpoint inhibitor type</td>
<td></td>
</tr>
<tr>
<td>PD-1</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>PD-L1</td>
<td>5 (35.7)</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>0</td>
</tr>
<tr>
<td>Cancer type</td>
<td></td>
</tr>
<tr>
<td>Non-small cell lung carcinoma</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>Pharyngeal carcinoma</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Esophageal carcinoma</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Cancer stage</td>
<td></td>
</tr>
<tr>
<td>UICC III</td>
<td>0</td>
</tr>
<tr>
<td>UICC IV</td>
<td>14 (100)</td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td></td>
</tr>
<tr>
<td>Stool frequency (times/day)</td>
<td>9 (1–15)</td>
</tr>
<tr>
<td>Fever</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Bloody stool</td>
<td>6 (42.9)</td>
</tr>
<tr>
<td>CTCAE grade of colitis</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>2</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>3</td>
<td>11 (78.6)</td>
</tr>
<tr>
<td>4, 5</td>
<td>0</td>
</tr>
<tr>
<td>Time to colitis onset (day)</td>
<td>124 (12–459)</td>
</tr>
<tr>
<td>Other adverse events</td>
<td></td>
</tr>
<tr>
<td>Endocrine</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Hepatic</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Serum C-reactive protein (mg/dL)</td>
<td>4.7 (0.1–14.9)</td>
</tr>
<tr>
<td>Serum albumin (g/dL)</td>
<td>3.3 (2.5–4.3)</td>
</tr>
</tbody>
</table>

Values are presented as median (range) or number (%). PD-1, programmed cell death receptor 1; PD-L1, PD-ligand 1; UICC, Union for International Cancer Control; CTCAE, Common Terminology Criteria for Adverse Events.
Table 2. Visualization Rate in Each Colonic Segment Examined by Ultrasonography and Colonoscopy

<table>
<thead>
<tr>
<th>Colonic segment</th>
<th>Colonoscopy</th>
<th>Ultrasonography</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cecum</td>
<td>11 (78.6%)</td>
<td>13 (92.9%)</td>
<td>0.280</td>
</tr>
<tr>
<td>Ascending colon</td>
<td>11 (78.6%)</td>
<td>14 (100)</td>
<td>0.067</td>
</tr>
<tr>
<td>Right-sided transverse colon</td>
<td>11 (78.6%)</td>
<td>14 (100)</td>
<td>0.067</td>
</tr>
<tr>
<td>Left-sided transverse colon</td>
<td>13 (92.9%)</td>
<td>13 (92.9%)</td>
<td>NS</td>
</tr>
<tr>
<td>Descending colon</td>
<td>13 (92.9%)</td>
<td>13 (92.9%)</td>
<td>NS</td>
</tr>
<tr>
<td>Sigmoid colon</td>
<td>14 (100)</td>
<td>14 (100)</td>
<td>NS</td>
</tr>
<tr>
<td>Rectum</td>
<td>14 (100)</td>
<td>14 (100)</td>
<td>NS</td>
</tr>
<tr>
<td>All segments</td>
<td>87 (88.8%)</td>
<td>95 (96.9%)</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Values are presented as number (%).
*P-values were calculated using the chi-square test for categorical variables. NS, not significant.

Table 3. Endoscopic and Ultrasonographic Findings of Immune-Mediated Colitis

<table>
<thead>
<tr>
<th>Findings</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrasonographic findings</td>
<td></td>
</tr>
<tr>
<td>Thickened mucosa and submucosa</td>
<td>14 (100)</td>
</tr>
<tr>
<td>Loss of stratification</td>
<td>8 (57.1)</td>
</tr>
<tr>
<td>Irregular mucosa or hyperechogenic shallow concavity in the mucosa, which suggested ulceration</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Increased blood flow signals</td>
<td>13 (92.9)</td>
</tr>
<tr>
<td>Echo level increase of mesenteric adipose tissue</td>
<td>3 (21.4)</td>
</tr>
<tr>
<td>Endoscopic findings</td>
<td></td>
</tr>
<tr>
<td>Exudates</td>
<td>4 (28.6)</td>
</tr>
<tr>
<td>Loss of vascular pattern</td>
<td>12 (85.7)</td>
</tr>
<tr>
<td>Granular or edematous mucosa</td>
<td>11 (78.6)</td>
</tr>
<tr>
<td>Patch or diffuse erythema</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>Aphthae</td>
<td>11 (78.6)</td>
</tr>
<tr>
<td>Ulceration</td>
<td>3 (21.4)</td>
</tr>
<tr>
<td>Contact and spontaneous bleeding</td>
<td>6 (42.9)</td>
</tr>
</tbody>
</table>

Table 4. BWT, CDS Grade, US Grade, and UCEIS of Severity of Each Colonic Segment

<table>
<thead>
<tr>
<th>Colonic segment</th>
<th>BWT (mm)</th>
<th>CDS grade</th>
<th>US grade</th>
<th>UCEIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cecum</td>
<td>3.7 (1.7–9.8)</td>
<td>2.0 (0–3.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>1.0 (0.0–3.0)</td>
</tr>
<tr>
<td>Ascending colon</td>
<td>3.9 (1.7–10.1)</td>
<td>1.5 (0–3.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>3.0 (0.0–5.0)</td>
</tr>
<tr>
<td>Right-sided transverse colon</td>
<td>5.1 (1.5–10.6)</td>
<td>2.0 (0–2.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>1.0 (0.0–5.0)</td>
</tr>
<tr>
<td>Left-sided transverse colon</td>
<td>3.8 (1.5–7.7)</td>
<td>2.0 (0–3.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>1.0 (0.0–5.0)</td>
</tr>
<tr>
<td>Descending colon</td>
<td>4.7 (2.0–10.7)</td>
<td>0.5 (0–3.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>1.0 (0.0–5.0)</td>
</tr>
<tr>
<td>Sigmoid colon</td>
<td>3.2 (1.9–6.8)</td>
<td>2.0 (0–2.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>3.0 (2.0–5.0)</td>
</tr>
<tr>
<td>Rectum</td>
<td>7.9 (5.8–12.5)</td>
<td>0.0 (0–2.0)</td>
<td>2.0 (1.0–4.0)</td>
<td>3.0 (1.0–5.0)</td>
</tr>
<tr>
<td>Most severe lesions</td>
<td>8.4 (5.8–12.5)</td>
<td>2.0 (0–3.0)</td>
<td>3.0 (1.0–4.0)</td>
<td>3.5 (2.0–5.0)</td>
</tr>
</tbody>
</table>

Values are presented as median (range).
BWT, bowel wall thickness; CDS, color Doppler signal; US, ultrasonography; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.
Table 4 shows the BWT, CDS grade, US grade, and UCEIS in each segment of the large intestine. The median BWT, CDS grade, US grade, and UCEIS at the most severely affected site in each patient were 8.4 mm, 2, 3, and 3.5, respectively.

The correlations at the most severely affected sites for each score are shown in Table 5 and Fig. 2. A moderate correlation was found between BWT and UCEIS ($r=0.628$, $P=0.020$), while no significant correlation was found between BWT and CTCAE. The CDS grade and UCEIS showed no significant correlation. However, the CDS grade and CTCAE were strongly correlated ($r=0.724$, $P=0.008$) (Fig. 2). The correlations at the most severely affected sites for each score are shown in Table 5 and Fig. 2. A moderate correlation was found between BWT and UCEIS ($r=0.628$, $P=0.020$), while no significant correlation was found between BWT and CTCAE. The CDS grade and UCEIS showed no significant correlation. However, the CDS grade and CTCAE were strongly correlated ($r=0.724$, $P=0.008$) (Fig. 2). The US grade and UCEIS showed a significant correlation in the sigmoid colon and the rectum, while no significant correlation in the other segments. Moderate correlations were also observed between the US grade and serum CRP levels or serum albumin levels (Table 5). Since it has been reported that the diagnostic accuracy of ultrasound in inflammatory bowel disease is low in the rectum,\(^4\) we adopted the values for the most severely affected sites in the colon, excluding the rectum, and analyzed the correlation between endoscopic severity and US findings (Supplementary Fig. 3). As a result, we found a strong correlation between BWT and UCEIS ($r=0.787$, $P=0.005$).

Correlations were calculated using Spearman correlation coefficient. \(^a\)Comparison at the most severely affected sites.

BWT, bowel wall thickness; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; CTCAE, Common Terminology Criteria for Adverse Events; CDS, color Doppler signal; US, ultrasonography.

### Table 5. Correlation of Each Score and Serum C-Reactive Protein and Albumin

<table>
<thead>
<tr>
<th>Correlations</th>
<th>r</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BWT and UCEIS(^a)</td>
<td>0.628</td>
<td>0.020</td>
</tr>
<tr>
<td>BWT and CTCAE(^a)</td>
<td>0.469</td>
<td>0.099</td>
</tr>
<tr>
<td>CDS grade and UCEIS(^a)</td>
<td>0.445</td>
<td>0.117</td>
</tr>
<tr>
<td>CDS grade and CTCAE(^a)</td>
<td>0.724</td>
<td>0.008</td>
</tr>
<tr>
<td>US grade and UCEIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cecum</td>
<td>0.311</td>
<td>0.379</td>
</tr>
<tr>
<td>Ascending colon</td>
<td>0.582</td>
<td>0.064</td>
</tr>
<tr>
<td>Right-sided transverse colon</td>
<td>0.312</td>
<td>0.333</td>
</tr>
<tr>
<td>Left-sided transverse colon</td>
<td>0.270</td>
<td>0.386</td>
</tr>
<tr>
<td>Descending colon</td>
<td>0.191</td>
<td>0.546</td>
</tr>
<tr>
<td>Sigmoid colon</td>
<td>0.616</td>
<td>0.020</td>
</tr>
<tr>
<td>Rectum</td>
<td>0.707</td>
<td>0.005</td>
</tr>
<tr>
<td>Most severe lesions</td>
<td>0.687</td>
<td>0.009</td>
</tr>
<tr>
<td>US grade and CTCAE(^a)</td>
<td>0.628</td>
<td>0.035</td>
</tr>
<tr>
<td>US grade and C-reactive protein(^a)</td>
<td>0.244</td>
<td>0.398</td>
</tr>
<tr>
<td>US grade and albumin(^a)</td>
<td>-0.330</td>
<td>0.248</td>
</tr>
</tbody>
</table>

Fig. 2. Correlations between BWT, CDS grade, UCEIS, and CTCAE grade of colitis. (A) A moderate correlation was found between BWT and UCEIS, (B) while no significant correlation was found between BWT and CTCAE. (C) The CDS grade and UCEIS showed no significant correlation. (D) However, the CDS grade and CTCAE were strongly correlated. BWT, bowel wall thickness; CDS, color Doppler signal; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; CTCAE, Common Terminology Criteria for Adverse Events.
**DISCUSSION**

US findings of IMC were thickening of the mucosal and submucosal layer, loss of stratification, irregular mucosa or hyperechogenic shallow concavity in the mucosal lumen which suggests ulceration, as well as color Doppler images revealed an increased blood flow signals in the intestinal wall. There were correlations between the severity of BWT and UCEIS, and the CDS grade and the CTCAE grade of colitis. Also, US grades and UCEIS, and CTCAE showed significant correlations.

The diagnosis of IMC is basically established based on CS findings and the gold standard to evaluate IMC is CS. However, CS has several disadvantages. Due to limitations in terms of cost, inconvenience, and invasiveness, CS is not suitable for frequent monitoring. Further, in patients with severe colitis, the procedure poses risks of intestinal perforation and aggravation of disease activity. In the other hand, US offers advantages such as no radiation exposure, noninvasiveness, low cost, can be performed the procedure regardless of the patient’s condition, and ability to perform real-time scanning. In recent years, the development of US equipments and testing technology has popularized the use of US in the field of gastrointestinal diseases. US has been found useful in CD, UC, and graft-versus-host disease enterocolitis, and its findings correlated with those of endoscopy. To the best of our knowledge, there has been only 1 case report in which intestinal US was used in IMC. Therefore, our study analyzed the features of US findings in IMC, as well as their correlation with endoscopic findings, CTCAE grade, and CRP. The US findings showed a correlation between UCEIS and CTCAE. Regarding visualization, the total visualization rates in all segments were significantly higher in US than in CS. In the ascending colon

---

**Table 6. Diagnostic Accuracy of BWT, CDS Grade and US Grade for the Diagnosis of UCEIS and CTCAE of Colitis in Immune-Mediated Colitis**

<table>
<thead>
<tr>
<th>Accuracy</th>
<th>UCEIS ≥ 5</th>
<th>CTCAE grade of colitis ≥ 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BWT (mm)</td>
<td>CDS grade</td>
</tr>
<tr>
<td>AUROC</td>
<td>0.800</td>
<td>0.675</td>
</tr>
<tr>
<td>Cutoff value</td>
<td>10.4</td>
<td>2.0</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>0.750</td>
<td>1.000</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.900</td>
<td>0.400</td>
</tr>
<tr>
<td>PPV</td>
<td>0.750</td>
<td>0.400</td>
</tr>
<tr>
<td>NPV</td>
<td>0.900</td>
<td>1.000</td>
</tr>
</tbody>
</table>

BWT, bowel wall thickness; CDS, color Doppler signal; US, ultrasonography; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; CTCAE, Common Terminology Criteria for Adverse Events; AUROC, area under receiver operating curve; PPV, positive predictive value; NPV, negative predictive value.

---

**4. Case Presentation**

Fig. 3 shows CS findings and US findings before and after treatment in a patient who had developed IMC as a result of an anti-PD-L1 antibody therapy (durvalumab). Her condition was resistant to steroids and anti-tumor necrosis factor α antibodies, and remission was induced using vedolizumab. At the onset of colitis, US showed the intestinal wall thickness and partially indistinct stratification, and color Doppler showed increased blood flow signals (Fig. 3A and B). CS showed a circumferential erosion from the cecum to the rectum, and there was exudates and spontaneous bleeding (Fig. 3C). After vedolizumab therapy, US showed improvement of the bowel wall thickening, and the stratified structure became clearly visible, and color Doppler showed no blood flow signals (Fig. 3D and E). Also, CS showed disappearance of the erosion and exudates, and the mucosal vascular pattern became visible (Fig. 3F).
and the right transverse colon, visualization rates also tended to be higher in US. In IMC, patients have a poor general condition, and other concomitant irAEs may also be present. Hence total CS may not be feasible in many cases. Our findings regarding visualization showed the remarkable advantages of US, which is less invasive and does not require pretreatment. Similar to previous reports, the endoscopic findings from our study showed many properties similar to those of UC. Many of the US findings recorded in our study were similar to US findings associated with UC. Meanwhile, in some cases, inflammatory findings such as thickening and loss of stratification were found in the submucosa despite the absence of active inflammatory findings such as thickening in the mucosal layer. This finding is different from those associated with UC, in which inflammation arises from the superficial layer of the mucosa. This may reflect the differences between the underlying mechanisms of IMC and UC. Another finding that differed from UC was that the inflammation was not continuous from the rectum but scattered in a skip-like pattern. The endoscopic or US findings of IMC were analyzed according to the type of ICI, but no significant difference in findings was observed. It has been previously reported that ipilimumab (CTLA-4 antibody) may cause a high incidence of rectal or sigmoid colon inflammation, but to our knowledge, no difference in IMC findings between PD-1 and PD-L1 antibodies has been reported. Similarly, in this study, there was no significant difference in US findings between PD-1 and PD-L1 antibodies.

There were several limitations to this study. The first was that since there has been no proposed method for evaluating the US and CS severity in IMC, the scoring method for UC was used alternatively. The second limitation was that US was not performed in a standardized manner in all cases and that the administration of oral laxatives as a pretreatment for CS may have affected US findings. In patients who took bowel cleansing agent before US, the bowel wall may have stretched due to bowel cleansing agent, resulting in an underestimation of BWT. In addition, the study was conducted at a single facility, and the sample size was small. Studies in the future should consid-

---

**Fig. 3.** Ultrasonography and colonoscopy findings of immune-mediated colitis (IMC) in a patient who had anti-PD-L1 antibody therapy (durvalumab). IMC was resistant to steroids and anti-tumor necrosis factor α antibodies. The remission was induced using vedolizumab. At the onset of colitis, ultrasonography (US) shows a thickened bowel wall, the stratified structure is partially indistinct (arrows) (A), and color Doppler shows an increased blood flow signal (B). Colonoscopy (CS) shows a circular erosion from the cecum to the rectum, and there are exudates and spontaneous bleeding (C). After administering vedolizumab, US shows the bowel wall thickening improvement, and the stratified structure becomes clearly visible (arrows) (D), color Doppler shows no blood flow signal (E). CS findings improves that the erosion and exudates are disappeared, and the mucosal vascular pattern becomes also visible (F). PD-L1, programmed cell death receptor ligand 1.
er including a larger number of cases (sample size). A scoring method for US findings in IMC should be established.

In conclusion, our study revealed US findings of IMC, and US could be useful method for the evaluation and noninvasive monitoring of IMC based on correlation with CS findings and CTCAE grade.

**ADDITIONAL INFORMATION**

**Funding Source**
This work was supported by the Hokkaido University Hospital.

**Conflict of Interest**
No potential conflict of interest relevant to this article was reported.

**Data Availability Statement**
Not applicable.

**Author Contribution**

**Others**
We thank the staff of Hokkaido University Hospital for their invaluable help with data collection.

**ORCID**

<table>
<thead>
<tr>
<th>Author</th>
<th>ORCID ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sakurai K</td>
<td><a href="https://orcid.org/0000-0001-8178-8984">https://orcid.org/0000-0001-8178-8984</a></td>
</tr>
<tr>
<td>Katsurada T</td>
<td><a href="https://orcid.org/0000-0002-7400-2514">https://orcid.org/0000-0002-7400-2514</a></td>
</tr>
<tr>
<td>Nishida M</td>
<td><a href="https://orcid.org/0000-0002-8406-7311">https://orcid.org/0000-0002-8406-7311</a></td>
</tr>
<tr>
<td>Omotehara S</td>
<td><a href="https://orcid.org/0000-0003-0415-4587">https://orcid.org/0000-0003-0415-4587</a></td>
</tr>
<tr>
<td>Fukushima S</td>
<td><a href="https://orcid.org/0000-0003-4466-5808">https://orcid.org/0000-0003-4466-5808</a></td>
</tr>
<tr>
<td>Otagiri S</td>
<td><a href="https://orcid.org/0000-0002-2209-9334">https://orcid.org/0000-0002-2209-9334</a></td>
</tr>
<tr>
<td>Nagashima K</td>
<td><a href="https://orcid.org/0000-0003-0528-0390">https://orcid.org/0000-0003-0528-0390</a></td>
</tr>
</tbody>
</table>

**Onishi R** https://orcid.org/0000-0002-0353-4839
**Takagi R** https://orcid.org/0000-0002-5930-0329
**Komatsu Y** https://orcid.org/0000-0002-1570-6802
**Sakamoto N** https://orcid.org/0000-0003-0061-059X

**Supplementary Material**
Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

**REFERENCES**


